Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B2E5-ADC
- Development stage
- Preclinical
- Lead developer
- Hokkaido University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intratumoral
01
Overview
B2E5-ADC is an experimental antibody-drug conjugate (ADC) designed to target epithelial-V–like antigen 1 (EVA1), a protein identified as a functional factor specifically expressed in glioblastoma-initiating cells (GICs). The therapeutic candidate consists of the B2E5 monoclonal antibody, which was generated by immunizing mice with an EVA1-Fc fusion protein and selected for its high affinity to human EVA1. In preclinical studies, B2E5-ADC demonstrated potent cytotoxicity against EVA1-expressing cell lines and GICs in vitro. Furthermore, the conjugate showed efficacy in preventing tumorigenesis when administered intracranially in GIC tumor-bearing mouse models. Beyond direct payload delivery, the B2E5 antibody component also mediates cell death through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The development of B2E5-ADC is a collaborative effort involving researchers from Hokkaido University and RIKEN.
- Other names
- B2E5 antibody-drug conjugateB-2E5 antibody-drug conjugateB 2E5 antibody-drug conjugateEVA1-antibody drug conjugateEVA-1-antibody drug conjugateEVA 1-antibody drug conjugate
02
Targets
C1Q (Complement C1q)EVA1A (Eva-1 homolog A, regulator of programmed cell death)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on B2E5-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B2E5-ADC.